Search
Monte Rosa Therapeutics Inc
GLUEAdd to Watchlist
16.520USD
-6.160-27.16%
Close 07-31 16:00（ET）Quotes delayed by 15 min
1.40BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Monte Rosa Therapeutics Inc is 8.67, ranking 74 out of 385 in the Biotechnology & Medical Research industry. The average price target is 18.00, with a high of 20.00 and a low of 13.00.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
33.600
Target Price
+103.39%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Monte Rosa Therapeutics Inc
GLUE
9
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
Kymera Therapeutics Inc
KYMR
24
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Monte Rosa Therapeutics Inc's expected revenue for the next quarter?
Monte Rosa Therapeutics Inc's expected revenue is 5.52M.
What is Monte Rosa Therapeutics Inc's price target?
Analysts forecast that Monte Rosa Therapeutics Inc's price target is USD 18.00, with the highest forecast at USD 20.00 and the lowest forecast at USD 13.00.
How have Monte Rosa Therapeutics IncGLUE's recent earnings per share performed?
The market expectation was USD -0.45, while Monte Rosa Therapeutics IncGLUE's earnings per share (EPS) for the previous quarter was USD -0.54. EPS for the next quarter is expected at USD -0.38.
What is the analyst rating for Monte Rosa Therapeutics Inc?
Based on the ratings of Monte Rosa Therapeutics Inc's stock from 9 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.